Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.00 | -0.33 | 0.37 |
| FCF Yield | 4.70% | 9.12% | -0.28% | 4.88% |
| EV / EBITDA | 17.38 | 5.49 | 24.03 | 16.87 |
| Quality | ||||
| ROIC | 15.92% | 42.47% | 10.19% | 14.50% |
| Gross Margin | 93.16% | 95.57% | 91.73% | 89.95% |
| Cash Conversion Ratio | 0.86 | 0.51 | -0.08 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 28.68% | 28.37% | 16.16% | 14.24% |
| Free Cash Flow Growth | -21.34% | 3,519.60% | -106.17% | -33.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.12 | 1.10 | 0.18 |
| Interest Coverage | 15.01 | 32.61 | 6.89 | 8.52 |
| Efficiency | ||||
| Inventory Turnover | 0.23 | 0.43 | 0.95 | 0.96 |
| Cash Conversion Cycle | 376.96 | 97.93 | 84.50 | 106.43 |